WO2012124982A3 - Préparation orale ayant un enrobage entérique - Google Patents

Préparation orale ayant un enrobage entérique Download PDF

Info

Publication number
WO2012124982A3
WO2012124982A3 PCT/KR2012/001846 KR2012001846W WO2012124982A3 WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3 KR 2012001846 W KR2012001846 W KR 2012001846W WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral preparation
enteric coating
relates
present
zoledronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/001846
Other languages
English (en)
Korean (ko)
Other versions
WO2012124982A2 (fr
Inventor
이재걸
전호성
김진모
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of WO2012124982A2 publication Critical patent/WO2012124982A2/fr
Publication of WO2012124982A3 publication Critical patent/WO2012124982A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation orale contenant de l'acide zolédronique, qui réduit des lésions entériques et améliore la biodisponibilité. Plus particulièrement, la présente invention concerne une préparation orale ayant un enrobage entérique, qui comprend de l'acide zolédronique et les sels pharmaceutiquement acceptables de celui-ci, et qui présente un noyau, dont le niveau de pH est de 3,5 à 7.
PCT/KR2012/001846 2011-03-16 2012-03-14 Préparation orale ayant un enrobage entérique Ceased WO2012124982A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110023362A KR20120105738A (ko) 2011-03-16 2011-03-16 장용코팅된 경구용 제제
KR10-2011-0023362 2011-03-16

Publications (2)

Publication Number Publication Date
WO2012124982A2 WO2012124982A2 (fr) 2012-09-20
WO2012124982A3 true WO2012124982A3 (fr) 2012-11-08

Family

ID=46831213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001846 Ceased WO2012124982A2 (fr) 2011-03-16 2012-03-14 Préparation orale ayant un enrobage entérique

Country Status (2)

Country Link
KR (1) KR20120105738A (fr)
WO (1) WO2012124982A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997378A1 (fr) * 2015-09-18 2017-03-23 Thar Pharma, Llc Procede de cristallisation et biodisponibilite

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (fr) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Compositions de risedronate a liberation lente
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (fr) * 1999-04-09 2000-10-19 Astrazeneca Ab Formulation pharmaceutique comprenant un bisphosphonate et un agent d'addition favorisant l'absorption du bisphosphonate
WO2001032185A1 (fr) * 1999-11-02 2001-05-10 Cipla Ltd. Composition pharmaceutique renfermant au moins un acide bisphosphonique ou un de ses sels et son procede de preparation
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (ko) * 2004-07-30 2006-10-09 주식회사 유유 생체이용율이 증진된 알렌드론산 제제
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (fr) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Compositions de risedronate a liberation lente
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (fr) * 1999-04-09 2000-10-19 Astrazeneca Ab Formulation pharmaceutique comprenant un bisphosphonate et un agent d'addition favorisant l'absorption du bisphosphonate
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
WO2001032185A1 (fr) * 1999-11-02 2001-05-10 Cipla Ltd. Composition pharmaceutique renfermant au moins un acide bisphosphonique ou un de ses sels et son procede de preparation
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (ko) * 2004-07-30 2006-10-09 주식회사 유유 생체이용율이 증진된 알렌드론산 제제

Also Published As

Publication number Publication date
WO2012124982A2 (fr) 2012-09-20
KR20120105738A (ko) 2012-09-26

Similar Documents

Publication Publication Date Title
WO2009066326A3 (fr) Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables
WO2011012816A3 (fr) Formulation pharmaceutique
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
WO2011157721A3 (fr) Composition pharmaceutique contenant de l'ivabradine
EP2621284A4 (fr) Procédé de préparation d'un concentré aqueux de glyphosate
WO2014041565A3 (fr) Procédé amélioré pour la préparation de vilantérol et de ses intermédiaires
WO2012056458A3 (fr) Composés intermédiaires et procédé de préparation de fingolimod
WO2014064255A3 (fr) Capsules
WO2012001705A3 (fr) Compositions pharmaceutiques de (r)-lansoprazole
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
WO2009117381A3 (fr) Préparation de montélukast et ses sels
ZA201107412B (en) Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2008049922A3 (fr) Nouveau procédé de préparation du montélukast
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
IL225557A0 (en) Method for preparing (3s,3s') 4,4'-disulfanedilbis (3-aminobutane 1- sulfonic acid)
WO2012112841A3 (fr) Préparation de sels d'acide [1,2,4]oxadiazol-3-yl]-ylique et formes cristallines et leur préparation
WO2013017910A8 (fr) Compositions pharmaceutiques à libération prolongée contenant de la palipéridone
BRPI1012007A2 (pt) "método para a preparação de ácido 2-ceto-carboxílico"
WO2012018791A3 (fr) Préparation de chlorhydrate de prasugrel
WO2012014052A3 (fr) Nouvelles compositions pharmaceutiques à libération prolongée enrobées contenant de la palipéridone
WO2011136513A3 (fr) Composition de greffe osseuse ou d'obturation osseuse comprenant un dérivé d'acide dihydroxybenzoïque
WO2010134048A3 (fr) Solutions de rétinoïdes topiques
WO2012124982A3 (fr) Préparation orale ayant un enrobage entérique
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
IL225680A0 (en) Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2